BACKGROUND:Mycobacterium abscessus species (MABS) is now a most virulent rapidly growing mycobacteria (RGM), and the rapid increase of MABS was recently observed worldwide, including in Japan. Thus, we gathered evidences of the presence of pulmonary MABS in Japanese population from Japanese articles.METHODS:we searched studies that addressed the isolation of pulmonary non-tuberculous Mycobacteria (NTM) or MABS from clinical respiratory specimens in Japan.RESULTS:the ratio of MABS to NTM was 3.04% (95% confidence interval [CI]: 2.51-3.68), found using the meta-analysis of single proportions. The estimated mean age of patients infected with MABS was 67.72 years (95% CI: 65.41-70.02), found using the meta-analysis of single means. The estimated proportion of females, never smoker, and the co-infection with Mycobacterium avium complex (MAC) was 66.75% (95% CI: 59.23-73.50), 67.57% (95% CI: 62.43-72.32), and 36.74% (95% CI: 25.30-49.90), respectively. The characteristics of MABS in Japan were considerably different from that in Europe and United States from the perspective of age, gender, and complications, wherein the patients in these countries tended to be younger, had lower number of females, and had more occurrences of hereditary diseases, including cystic fibrosis (CF).CONCLUSION:we hypothesized that the characteristics of MABS in the Japanese were involved in those of non-CF MABS, and the distribution of gender and age of MABS were similar to that of MAC in the Japanese.

Background:The coronavirus disease 2019 (COVID-19) is a condition caused by the novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Although several papers have reported the presence bradycardia in patients with COVID-19, the pathophysiology behind this remains unclear. Therefore, we investigated the presence of bradycardia in patients with COVID-19.Methods:We conducted a retrospective cohort study in a total of 153 patients with COVID-19 and 90 patients with influenza who were hospitalized in our hospital from January 1, 2020 to December 31, 2021 and from January 1, 2014 to December 31, 2021, respectively. Data were collected from patient medical records, which included sex, age, duration of hospitalization, pneumonia complications, supplemental oxygen therapy, antiviral treatment, past history, and vital signs.Results:After adjustment, the incidence of bradycardia and steroid use in patients with COVID-19 were significantly higher than those in patients with influenza (P=0.007 and P<0.001, respectively). We then compared the detailed characteristics of patients with COVID-19 to evaluate risk factors for bradycardia. Multivariate logistic regression analysis revealed that steroid use was significantly related to bradycardia [P=0.031; odds ratio (OR): 3.67; 95% confidence interval (CI): 1.12-11.96]. Overall, results showed a higher incidence of bradycardia in patients with COVID-19 who received steroid treatment.Conclusions:Our results showed that steroid treatment in patients with COVID-19 may be associated with the incidence of bradycardia.

OR) 1.09, 95% CI 1.05-1.14,P<0.01] and C-reactive protein (OR 1.10, 95% CI 1.01-1.19,P=0.023) levels were

Background and Aims: The aims are to investigate whether repeat re-biopsy raise the positive rate of T790M and to compare the efficacy of osimertinib between in the first rebiopsy and repeat re-biopsy in patients with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC).Methods: We retrospectively assessed the efficacy repeat rebiopsy and osimertinib in 49 patients to undergo re-biopsy after disease progression of the first or the second generation EGFR tyrosine kinase inhibitor (TKI).Results: Of 49 patients, 26 were male, and the median age was 71 (range, 50-89 years).The type of EGFR mutation was as follows: 23 patients had exon 19 deletion, 23 had exon 21 L858R, and 3 had others.The positive rate of T790M was 43% (17/40) in tissue and 32% (12/38) in plasma.Although the positive rate of T790M in the first re-biopsy was 31%, repeat re-biopsy raised 59%.The response rate, median time to progression, median survival time of osimertinib were 60.0%, 18 months, and 45 months in patients with the first re-biopsy positive, and 69.2%, 10 months, and 59 months in patients with the second or after re-biopsy positive, respectively.There were no differences in response rates, progression free survivals, and overall survivals between patients in the first re-biopsy positive and the second or after re-biopsy positive. Conclusion:The repeat re-biopsy raised the positive rate of T790M from 31% to 59%.

Background and Aims: The aims are to investigate whether repeat re-biopsy raise the positive rate of T790M and to compare the efficacy of osimertinib between in the first rebiopsy and repeat re-biopsy in patients with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC).Methods: We retrospectively assessed the efficacy repeat rebiopsy and osimertinib in 49 patients to undergo re-biopsy after disease progression of the first or the second generation EGFR tyrosine kinase inhibitor (TKI).Results: Of 49 patients, 26 were male, and the median age was 71 (range, 50-89 years).The type of EGFR mutation was as follows: 23 patients had exon 19 deletion, 23 had exon 21 L858R, and 3 had others.The positive rate of T790M was 43% (17/40) in tissue and 32% (12/38) in plasma.Although the positive rate of T790M in the first re-biopsy was 31%, repeat re-biopsy raised 59%.The response rate, median time to progression, median survival time of osimertinib were 60.0%, 18 months, and 45 months in patients with the first re-biopsy positive, and 69.2%, 10 months, and 59 months in patients with the second or after re-biopsy positive, respectively.There were no differences in response rates, progression free survivals, and overall survivals between patients in the first re-biopsy positive and the second or after re-biopsy positive. Conclusion:The repeat re-biopsy raised the positive rate of T790M from 31% to 59%.

RespirologyVolume 26, Issue S3 p. 327-327 AbstractsFree Access P8-98: Withdrawn First published: 19 November 2021 https://doi.org/10.1111/resp.14150_610AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume26, IssueS3Supplement: The 25th Congress of the Asian Pacific Society of Respirology (APSR 2021), Hybrid – In person and Virtual, 20‐21 November 2021, KyotoNovember 2021Pages 327-327 RelatedInformation